SwePub
Sök i LIBRIS databas

  Extended search

id:"swepub:oai:DiVA.org:oru-74049"
 

Search: id:"swepub:oai:DiVA.org:oru-74049" > Plasma Fatty Acid P...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Plasma Fatty Acid Profiles in Relation to Cognition and Gender in Alzheimer's Disease Patients During Oral Omega-3 Fatty Acid Supplementation : The OmegAD Study

Eriksdotter, Maria (author)
Karolinska Institutet
Vedin, Inger (author)
Karolinska Institutet
Falahati, Farshad (author)
Karolinska Institutet
show more...
Freund-Levi, Yvonne, 1956- (author)
Department of Neurobiology, Care Sciences and Society (NVS), Division of Clinical Geriatrics, Karolinska Institutet, Huddinge, Stockholm,Karolinska Inst, Dept Neurobiol Care Sci & Soc NVS, Div Clin Geriatr, Huddinge, Sweden.
Hjorth, Erik (author)
Karolinska Institutet
Faxen-Irving, Gerd (author)
Karolinska Institutet
Wahlund, Lars-Olof (author)
Karolinska Institutet
Schultzberg, Marianne (author)
Karolinska Institutet
Basun, Hans (author)
Uppsala universitet,Geriatrik
Cederholm, Tommy (author)
Karolinska Institutet,Uppsala universitet,Klinisk nutrition och metabolism
Palmblad, Jan (author)
Karolinska Institutet
show less...
 (creator_code:org_t)
IOS Press, 2015
2015
English.
In: Journal of Alzheimer's Disease. - : IOS Press. - 1387-2877 .- 1875-8908. ; 48:3, s. 805-812
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • BACKGROUND: ω3 fatty acids (ω3 FAs) may slow the rate of decline in cognitive performance in mild forms of cognitive impairment and Alzheimer's disease (AD). However, the relationship between changes of plasma ω3 FA levels and cognitive performance, as well as effects of gender, are poorly known.OBJECTIVE: To study the effect of 6-month administration of DHA-rich ω3 FA supplementation on plasma FA profiles in patients with mild to moderate AD in relation to cognitive performance and gender. This investigation is part of the OmegAD Study.METHODS: 174 AD patients (74 ± 9 years) were randomized to a daily intake of 2.3 g ω3 FA or placebo for 6 months; subsequently all received the ω3 FA preparation for the next 6 months. Baseline as well as changes in plasma levels of the main ω3 FAs in 165 patients, while receiving ω3 FA supplementation for 6 months, were analyzed for association to cognitive performance (assessed by ADAS-cog and MMSE scores) as well as to gender.RESULTS: Preservation of cognitive functioning, assessed by ADAS-cog or its sub-items (but not MMSE) scores, was significantly associated to increasing plasma ω3 FA levels over time. Thus, the higher ω3 FA plasma levels rose, the lower was the rate of cognitive deterioration. This effect was not related to gender; since although females displayed higher ω3 FA plasma levels than did males after 6 months of supplementation, this difference disappeared when adjusted for body weight.CONCLUSIONS: Since our study suggests dose-response relationships between plasma levels of ω3 FA and preservation of cognition, future ω3 FA trials in patients with mild AD should consider exploring graded (and body weight adjusted) doses of ω3 FA.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Neurologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Neurology (hsv//eng)

Keyword

Alzheimer’s disease
ClinicalTrials.gov identifier: NCT00211159
DHA
EPA
cognition
gender
ω3 fatty acids

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view